




PATENT
Docket No. 350292001300

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Alexandria, Virginia, on July 1, 2004.


Chimin Taylor

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Masaaki KOSAKA et al.

Serial No.: 10/069,290

Filing Date: August 21, 2002

For: EXPRESSION ENHANCER FOR HM
1.24 ANTIGEN

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR 1.97 & 1.98**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.97 and 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents listed on the Form PTO-1449 were cited in a European Office Action mailed on April 6, 2004 (copy attached) directed to a counterpart foreign application.

Applicants would like to advise the Examiner that only two of the documents cited in the European Office Action are being provided as the remaining references were previously

furnished and listed on PTO-1449 forms with Information Disclosure Statements filed on February 25 and December 17, 2002.

This Supplemental Information Disclosure Statement is submitted before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 CFR 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the event that the transmittal letter is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 350292001300.

Dated: July 1, 2004

Respectfully submitted,

By: 
Barry E. Bretschneider
Registration No. 28,055

Morrison & Foerster LLP
1650 Tysons Boulevard
Suite 300
McLean, Virginia 22102
Telephone: (703) 760-7743
Facsimile: (703) 760-7777



Form PTO-1449		Docket Number 350292001300	Application Number 10/069,290
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Masaaki KOSAKA et al.	
		Filing Date August 21, 2002	Group Art Unit to be assigned
		Mailing Date July 1, 2004	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	1.	Toshihiko OHTOMO et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells", Biochemical and Biophysical Research Communications 258 (1999) pp. 583-591
	2.	M.J. Birnbaum et al., "Phosphorylation of the Oncogenic Transcription Factor Interferon Regulatory Factor 2 (IRF2) In Vitro and In Vivo", Journal of Cellular Biochemistry 66 (1997) pp. 175-183
	3.	Office Action Report from European Patent Office dated April 6, 2004
	4.	
	5.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.